Clinical Trials Sponsored by Lymphoma Research Foundation

Total 4503 results

Polish Lymphoma Research Group

Active, not recruiting

The Efficacy of Salvage BGD With autoSCT Consolidation in Advanced Classical HL Patients Not Responding to ABVD (BURGUND)

Hodgkin's Lymphoma

Poland
Polish Lymphoma Research Group

Terminated

Comparison of Methotrexate Versus Interferon-alfa 2b in Patients With Primary Cutaneous T-cell Lymphomas

Lymphoma, T-Cell, Cutaneous | Mycosis Fungoides

Poland
Polish Lymphoma Research Group

Completed

First-line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance. (PLRG4)

Follicular Lymphoma | Marginal Zone Lymphoma | Lymphoplasmacytic Lymphoma | Small Lymphocytic Lymphoma

Poland
Polish Lymphoma Research Group

Completed

Ofatumumab With IVAC Salvage Chemotherapy in Diffuse Large B Cell Lymphoma Patients (PLRG8)

Diffuse Large B Cell Lymphoma

Poland
Lymphoma Study Association
Fondation ARC

Terminated

R-ACVBP Versus R-CHOP in Patients Aged 60-65 With Diffuse Large B-cell Lymphoma

Lymphoma, Large-Cell, Diffuse

France, Switzerland, Belgium
Lymphoma Study Association
Fondation ARC

Completed

ACVBP Followed by ASCT in Patients With BCL-2 Positive Diffuse Large B-Cell Lymphoma

Lymphoma, Large-Cell, Diffuse

France, Belgium
The Lymphoma Academic Research Organisation
Lymphoma Study Association

Not yet recruiting

Golcadomide Post-CAR T-cell in R/R Aggressive Large B-cell Lymphoma Patients With High Risk of Relapse

Refractory High Grade B-Cell Lymphoma | Diffuse Large B-cell Lymphoma Refractory | Refractory Transformed B-cell Non-Hodgkin Lymphoma | Refractory Primary Mediastinal Large B-Cell Lymphoma

France
The Lymphoma Academic Research Organisation

Recruiting

Study of Tafasitamab and Lenalinomide Associated to Rituximab in Frontline Diffuse Large B-Cell Lymphoma Patients of 80 y/o or Older

DLBCL

France, Belgium
Polish Lymphoma Research Group
AstraZeneca

Active, not recruiting

Acalabrutinib in CLL and MCL Patients Subjected to Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT) (ACALLO)

Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Adverse Event | Chronic Graft-versus-host-disease | Response Rate

Poland
The Lymphoma Academic Research Organisation

Completed

Detection and Characterization of Residual Masses in Lymphomas (ADAMANTIUS)

Hodgkin Lymphoma | B-Cell Lymphoma

France
The Lymphoma Academic Research Organisation

Completed

Study of Brentuximab Vedotin in Patients With R/R PTCL Treated With Gemcitabine

Refractory Peripheral T-Cell Lymphoma | Relapsed Peripheral T-Cell Lymphoma

France, Belgium
The Lymphoma Academic Research Organisation

Completed

Study Of Nivolumab Alone, Or In Combination With Vinblastin In Patients With Classical Hodgkin Lymphoma

Hodgkin Lymphoma | Coexisting Medical Conditions

France, Belgium
The Lymphoma Academic Research Organisation

Completed

Study of Ibrutinib in Patients With Relapsed or Refractory Primary Central Nervous Lymphoma or Intraocular Lymphoma (iLOC)

Intraocular Lymphoma | Primary Central Nervous Lymphoma

France
The Lymphoma Academic Research Organisation

Completed

Efficacy of a Treatment With CHOP and Lenalidomide in First Line in Angioimmunoblastic T-cell Lymphoma (AITL)

T-cell Lymphoma

France, Belgium
The Lymphoma Academic Research Organisation

Completed

Study of Mini-Chop Plus Ofatumumab To Treat Cd 20+ Diffuse Large B-Cell Lymphoma In Patients Aged Over 80 Years

Non Previously Treated CD20+ Diffuse Large B-cell Lymphoma

Belgium, France
The Lymphoma Academic Research Organisation

Completed

The Combination of Rad001 and Rituximab In Patients With Non-hodgkin's Lymphomas ((RAD001-R))

Non-Hodgkin's Lymphomas

France
The Lymphoma Academic Research Organisation

Recruiting

Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma

Marginal Zone Lymphoma

France
The Lymphoma Academic Research Organisation

Active, not recruiting

Efficacy of Upfront and Maintenance Obinutuzumab in Mantle Cell Lymphoma Treated by DHAP and MRD Driven Maintenance (LyMa101)

Mantle Cell Lymphoma

France
The Lymphoma Academic Research Organisation

Active, not recruiting

R-CHOP + R-HAD vs R-CHOP Followed by Maintenance Lenalidomide + Rituximab vs Rituximab for Older Patients With MCL

Mantle Cell Lymphoma

France, Spain, Belgium, Netherlands, Germany, Poland, Portugal
The Lymphoma Academic Research Organisation

Active, not recruiting

Study of Pixantrone in CD20+ Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma

Aggressive Non-Hodgkin Lymphoma

France, Belgium
The Lymphoma Academic Research Organisation

Completed

Evaluation of Atezolizumab-Venetoclax-Obinutuzumab Combination in Relapse/Refractory Lymphomas

Follicular Lymphoma | Marginal Zone Lymphoma | Diffuse Large B Cell Lymphoma | Mucosa Associated Lymphoid Tissue

France
The Lymphoma Academic Research Organisation

Completed

Real Time Molecular Characterization of Diffuse Large B Cell Lymphoma (DLBCL) (RT3)

Diffuse Large B Cell Lymphoma

France
The Lymphoma Academic Research Organisation

Terminated

BRIEF Bendamustine and Rituximab In Elderly Follicular (BRIEF)

Follicular Lymphoma

France, Belgium
The Lymphoma Academic Research Organisation

Recruiting

Breast Implant-associated Anaplastic Large Cell Lymphoma (BIA-ALCL) Registry

Anaplastic Large Cell Lymphoma Associated With Breast Implants (BIA-ALCL)

Belgium, France
The Lymphoma Academic Research Organisation

Active, not recruiting

Treatment by a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy

Refractory Indolent Adult Non-Hodgkin Lymphoma | Refractory Mantle Cell Lymphoma | Diffuse Large B-Cell Lymphoma Refractory | Refractory Transformed B-cell Non-Hodgkin Lymphoma | Refractory Primary Mediastinal Large B-Cell Cell Lymphoma

France
The Lymphoma Academic Research Organisation

Completed

A Pilot Trial of AVD and Brentuximab Vedotin (SGN-35) in the Treatment of Stage III-IV HIV-associated Hodgkin Lymphoma (AMC-085)

HIV Infection | Stage III Adult Hodgkin Lymphoma | Stage IV Adult Hodgkin Lymphoma | HIV-associated Hodgkin Lymphoma

France
The Lymphoma Academic Research Organisation

Active, not recruiting

Axi-Cel as a 2nd Line Therapy in Patients With Relapsed/Refractory Aggressive B Lymphoma Ineligible to Autologous Stem Cell Transplantation

B-cell Lymphoma Recurrent | B-Cell Lymphoma Refractory

France, Belgium
The Lymphoma Academic Research Organisation

Completed

Study of OBINUTUZUMAB Combined to LENALIDOMIDE for the Treatment of Relapsed/Refractory Follicular and Aggressive B-cell Lymphoma

Follicular Lymphoma Patients (Phase IB) | Follicular and Agressive (DLBCL&MCL) B-cell Lymphoma Patients (Phase II)

France, Belgium
The Lymphoma Academic Research Organisation

Completed

Efficacy and Safety of Romidepsin CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma

Peripheral T-cell Lymphoma

Spain, France, Korea, Republic of, Italy, Germany, Singapore, Belgium, Portugal
The Lymphoma Academic Research Organisation

Completed

Brentuximab Vedotin as Consolidation Treatment in Patients With Stage I/II HL and PET Positivity After 2 Cycles of ABVD (BRAPP2)

Hodgkin Lymphoma

France
The Lymphoma Academic Research Organisation

Completed

Study of Lenalidomide Maintenance Versus Placebo in Responding Elderly Patients With DLBCL and Treated With R-CHOP (REMARC)

Lymphoma | Diffuse Large B-cell Lymphoma

Belgium, Switzerland, France, Australia, Spain, Israel, Austria, Portugal, Poland
The Lymphoma Academic Research Organisation

Completed

Bendamustine Study in Classical Hodgkin Lymphoma Patients Over 60 Treated by Prednisone, Vinblastine and Doxorubicin (PVAB)

Classical Hodgkin Lymphoma

France, Belgium
The Lymphoma Academic Research Organisation

Terminated

Study of Entospletinib (ENTO) in Newly Diagnosed DLBCL Patients With aaIPI>=1 Treated by Chemiotherapy

DLBCL

Belgium, France
The Lymphoma Academic Research Organisation

Completed

A Study of Escalating Doses of Romidepsin in Association With CHOP in the Treatment of Peripheral T-Cell Lymphomas (Ro-CHOP)

Peripheral T Cell Lymphoma

France
Celgene
The Lymphoma Academic Research Organisation

Active, not recruiting

Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma (RELEVANCE)

Follicular Lymphoma

United States, Japan
The Lymphoma Academic Research Organisation
Celgene

Active, not recruiting

Efficacy and Safety of Oral Azacitidine Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory AITL

Relapsed Angioimmunoblastic T-Cell Lymphoma | Refractory Angioimmunoblastic T-cell Lymphoma

France, Denmark, United Kingdom, Austria, Belgium
The Lymphoma Academic Research Organisation
Pfizer

Completed

Phase Ib/II Study of the Efficacy and Safety of the R-CMC544/R-GEMOX Combination in Diffuse Lage B-cell Lymphoma at First or Second Relapse

Diffuse Large B-Cell Lymphoma

France, Belgium
The Lymphoma Academic Research Organisation
Novartis

Completed

A Phase II Study of Oral JAK1/JAK2 Inhibitor INC424 in Adult Patients With Relapsed/Refractory Classical Hodgkin's Lymphoma (HIJAK)

Hodgkin's Lymphoma

France, Belgium
Ronald Levy
American Society of Clinical Oncology; Lymphoma Research Foundation

Completed

CPG 7909 + Local Radiotherapy in Recurrent Low-Grade Lymphomas

Mycosis Fungoides | Non-Hodgkin Lymphoma

United States
Polish Lymphoma Research Group
Roche Pharma AG

Terminated

Efficacy and Safety of Obinutuzumab Preemptive Treatment at the Time of the Molecular Relapse (OPERA-PLRG10)

Mantle Cell Lymphoma

Poland
The Lymphoma Academic Research Organisation
Celgene Corporation

Active, not recruiting

A Phase 3 Open Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy Followed by Rituximab in Subjects With Previously Untreated Follicular Lymphoma (RELEVANCE)

Follicular Lymphoma

Spain, Canada, France, Australia, Italy, Belgium, Germany, Portugal
The Lymphoma Academic Research Organisation
Epizyme, Inc.

Active, not recruiting

Study of Tazemetostat in Newly Diagnosed Diffuse Large B Cell and Follicular Lymphoma Patients Treated by Chemiotherapy (Epi-RCHOP)

Lymphoma | Follicular Lymphoma | DLBCL

France, Belgium
The Lymphoma Academic Research Organisation
Innate Pharma

Recruiting

Study of Lacutamab in Peripheral T-cell Lymphoma

Peripheral T Cell Lymphoma | Relapse/Recurrence

France, Spain, Belgium, Germany
The Lymphoma Academic Research Organisation
Daiichi Sankyo

Active, not recruiting

Study of Valemetostat Tosylate as a Single Agent in Patients With Relapse/Refractory B-cell Lymphoma

Lymphoma, B-Cell

France, Belgium
The Lymphoma Academic Research Organisation
Celgene Corporation

Completed

A Phase IB Study Of The BTKi CC-292 Combined With Lenalidomide In Adults Patients With Relapsed/Refractory B-Cell Lymphoma (CLEAR)

Relapsed/Refractory B-cell Lymphoma

France
The Lymphoma Academic Research Organisation
Pfizer; Takeda; Hôpital Necker-Enfants Malades; Fondation ARC

Completed

Prospective Study of the Prognostic Value of New Markers in Adults With ALK-positive Large Anaplastic Lymphoma

Anaplastic Large Cell Lymphoma, ALK-Positive

France
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI); Novartis; Lymphoma Research Foundation

Completed

Universal Granulocyte Macrophage-colony Stimulating Factor (GM-CSF)-Producing and GM.CD40L for Autologous Tumor Vaccine in Mantle Cell Lymphoma

Lymphoma

United States
The Lymphoma Academic Research Organisation
Centre Henri Becquerel

Completed

Revlimid Dose 25 mg in Association With (R-CHOP) in the Treatment Follicular Lymphoma (R2-CHOP2)

Follicular Lymphoma

France
The Lymphoma Academic Research Organisation
Millennium Pharmaceuticals, Inc.

Completed

Brentuximab Vedotin in Refractory/Relapsed Hodgkin Lymphoma Treated by ICE (BV-ICE)

Hodgkin Disease

France, Belgium
The Lymphoma Academic Research Organisation
Roche Pharma AG

Terminated

Study of Intratumoral Selicrelumab With Atezolizumab in Patients With Refractory or Relapsed B Cell Lymphoma

Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma

France

Clinical Trials Sponsored by Lymphoma Research Foundation

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Turkmenistan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations